Greater glucagon-like peptide-1 responses to oral glucose are associated with lower central and peripheral blood pressures

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

Greater glucagon-like peptide-1 responses to oral glucose are associated with lower central and peripheral blood pressures. / Lundgren, Julie R.; Faerch, Kristine; Witte, Daniel R.; Jonsson, Anna E.; Pedersen, Oluf; Hansen, Torben; Lauritzen, Torsten; Holst, Jens J.; Vistisen, Dorte; Jorgensen, Marit E.; Torekov, Signe S.; Johansen, Nanna B.

I: Cardiovascular Diabetology, Bind 18, Nr. 1, 130, 2019.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Lundgren, JR, Faerch, K, Witte, DR, Jonsson, AE, Pedersen, O, Hansen, T, Lauritzen, T, Holst, JJ, Vistisen, D, Jorgensen, ME, Torekov, SS & Johansen, NB 2019, 'Greater glucagon-like peptide-1 responses to oral glucose are associated with lower central and peripheral blood pressures', Cardiovascular Diabetology, bind 18, nr. 1, 130. https://doi.org/10.1186/s12933-019-0937-7

APA

Lundgren, J. R., Faerch, K., Witte, D. R., Jonsson, A. E., Pedersen, O., Hansen, T., ... Johansen, N. B. (2019). Greater glucagon-like peptide-1 responses to oral glucose are associated with lower central and peripheral blood pressures. Cardiovascular Diabetology, 18(1), [130]. https://doi.org/10.1186/s12933-019-0937-7

Vancouver

Lundgren JR, Faerch K, Witte DR, Jonsson AE, Pedersen O, Hansen T o.a. Greater glucagon-like peptide-1 responses to oral glucose are associated with lower central and peripheral blood pressures. Cardiovascular Diabetology. 2019;18(1). 130. https://doi.org/10.1186/s12933-019-0937-7

Author

Lundgren, Julie R. ; Faerch, Kristine ; Witte, Daniel R. ; Jonsson, Anna E. ; Pedersen, Oluf ; Hansen, Torben ; Lauritzen, Torsten ; Holst, Jens J. ; Vistisen, Dorte ; Jorgensen, Marit E. ; Torekov, Signe S. ; Johansen, Nanna B. / Greater glucagon-like peptide-1 responses to oral glucose are associated with lower central and peripheral blood pressures. I: Cardiovascular Diabetology. 2019 ; Bind 18, Nr. 1.

Bibtex

@article{d1c8ab75077347b6af0f040837631455,
title = "Greater glucagon-like peptide-1 responses to oral glucose are associated with lower central and peripheral blood pressures",
abstract = "Background and aim Cardiovascular diseases (CVDs) are globally the leading cause of death and hypertension is a significant risk factor. Treatment with glucagon-like peptide-1 (GLP-1) receptor agonists has been associated with decreases in blood pressure and CVD risk. Our aim was to investigate the association between endogenous GLP-1 responses to oral glucose and peripheral and central haemodynamic measures in a population at risk of diabetes and CVD. Methods This cross-sectional study included 837 Danish individuals from the ADDITION-PRO cohort (52{\%} men, median (interquartile range) age 65.5 (59.8 to 70.7) years, BMI 26.1 (23.4 to 28.5) kg/m(2), without antihypertensive treatment and known diabetes). All participants received an oral glucose tolerance test with measurements of GLP-1 at 0, 30 and 120 min. Aortic stiffness was assessed by pulse wave velocity (PWV). The associations between GLP-1 response and central and brachial blood pressure (BP) and PWV were assessed in linear regression models adjusting for age and sex. Results A greater GLP-1 response was associated with lower central systolic and diastolic BP of - 1.17 mmHg (95{\%} confidence interval (CI) - 2.07 to - 0.27 mmHg, P = 0.011) and - 0.74 mmHg (95{\%} CI - 1.29 to - 0.18 mmHg, P = 0.009), respectively, as well as lower brachial systolic and diastolic BP of - 1.27 mmHg (95{\%} CI - 2.20 to - 0.33 mmHg, P = 0.008) and - 1.00 (95{\%} CI - 1.56 to - 0.44 mmHg, P = 0.001), respectively. PWV was not associated with GLP-1 release (P = 0.3). Individuals with the greatest quartile of GLP-1 response had clinically relevant lower BP measures compared to individuals with the lowest quartile of GLP-1 response (central systolic BP: - 4.94 (95{\%} CI - 8.56 to - 1.31) mmHg, central diastolic BP: - 3.05 (95{\%} CI - 5.29 to - 0.80) mmHg, brachial systolic BP: - 5.18 (95{\%} CI - 8.94 to - 1.42) mmHg, and brachial diastolic BP: - 2.96 (95{\%} CI - 5.26 to - 0.67) mmHg). Conclusion Greater glucose-stimulated GLP-1 responses were associated with clinically relevant lower central and peripheral blood pressures, consistent with beneficial effects on the cardiovascular system and reduced risk of CVD and mortality. Trial registration ClinicalTrials.gov Identifier: NCT00237549. Retrospectively registered 10 October 2005",
keywords = "GLP-1, Cardiovascular disease, Central blood pressure, Peripheral blood pressure, Aortic stiffness",
author = "Lundgren, {Julie R.} and Kristine Faerch and Witte, {Daniel R.} and Jonsson, {Anna E.} and Oluf Pedersen and Torben Hansen and Torsten Lauritzen and Holst, {Jens J.} and Dorte Vistisen and Jorgensen, {Marit E.} and Torekov, {Signe S.} and Johansen, {Nanna B.}",
year = "2019",
doi = "10.1186/s12933-019-0937-7",
language = "English",
volume = "18",
journal = "Cardiovascular Diabetology",
issn = "1475-2840",
publisher = "BioMed Central Ltd.",
number = "1",

}

RIS

TY - JOUR

T1 - Greater glucagon-like peptide-1 responses to oral glucose are associated with lower central and peripheral blood pressures

AU - Lundgren, Julie R.

AU - Faerch, Kristine

AU - Witte, Daniel R.

AU - Jonsson, Anna E.

AU - Pedersen, Oluf

AU - Hansen, Torben

AU - Lauritzen, Torsten

AU - Holst, Jens J.

AU - Vistisen, Dorte

AU - Jorgensen, Marit E.

AU - Torekov, Signe S.

AU - Johansen, Nanna B.

PY - 2019

Y1 - 2019

N2 - Background and aim Cardiovascular diseases (CVDs) are globally the leading cause of death and hypertension is a significant risk factor. Treatment with glucagon-like peptide-1 (GLP-1) receptor agonists has been associated with decreases in blood pressure and CVD risk. Our aim was to investigate the association between endogenous GLP-1 responses to oral glucose and peripheral and central haemodynamic measures in a population at risk of diabetes and CVD. Methods This cross-sectional study included 837 Danish individuals from the ADDITION-PRO cohort (52% men, median (interquartile range) age 65.5 (59.8 to 70.7) years, BMI 26.1 (23.4 to 28.5) kg/m(2), without antihypertensive treatment and known diabetes). All participants received an oral glucose tolerance test with measurements of GLP-1 at 0, 30 and 120 min. Aortic stiffness was assessed by pulse wave velocity (PWV). The associations between GLP-1 response and central and brachial blood pressure (BP) and PWV were assessed in linear regression models adjusting for age and sex. Results A greater GLP-1 response was associated with lower central systolic and diastolic BP of - 1.17 mmHg (95% confidence interval (CI) - 2.07 to - 0.27 mmHg, P = 0.011) and - 0.74 mmHg (95% CI - 1.29 to - 0.18 mmHg, P = 0.009), respectively, as well as lower brachial systolic and diastolic BP of - 1.27 mmHg (95% CI - 2.20 to - 0.33 mmHg, P = 0.008) and - 1.00 (95% CI - 1.56 to - 0.44 mmHg, P = 0.001), respectively. PWV was not associated with GLP-1 release (P = 0.3). Individuals with the greatest quartile of GLP-1 response had clinically relevant lower BP measures compared to individuals with the lowest quartile of GLP-1 response (central systolic BP: - 4.94 (95% CI - 8.56 to - 1.31) mmHg, central diastolic BP: - 3.05 (95% CI - 5.29 to - 0.80) mmHg, brachial systolic BP: - 5.18 (95% CI - 8.94 to - 1.42) mmHg, and brachial diastolic BP: - 2.96 (95% CI - 5.26 to - 0.67) mmHg). Conclusion Greater glucose-stimulated GLP-1 responses were associated with clinically relevant lower central and peripheral blood pressures, consistent with beneficial effects on the cardiovascular system and reduced risk of CVD and mortality. Trial registration ClinicalTrials.gov Identifier: NCT00237549. Retrospectively registered 10 October 2005

AB - Background and aim Cardiovascular diseases (CVDs) are globally the leading cause of death and hypertension is a significant risk factor. Treatment with glucagon-like peptide-1 (GLP-1) receptor agonists has been associated with decreases in blood pressure and CVD risk. Our aim was to investigate the association between endogenous GLP-1 responses to oral glucose and peripheral and central haemodynamic measures in a population at risk of diabetes and CVD. Methods This cross-sectional study included 837 Danish individuals from the ADDITION-PRO cohort (52% men, median (interquartile range) age 65.5 (59.8 to 70.7) years, BMI 26.1 (23.4 to 28.5) kg/m(2), without antihypertensive treatment and known diabetes). All participants received an oral glucose tolerance test with measurements of GLP-1 at 0, 30 and 120 min. Aortic stiffness was assessed by pulse wave velocity (PWV). The associations between GLP-1 response and central and brachial blood pressure (BP) and PWV were assessed in linear regression models adjusting for age and sex. Results A greater GLP-1 response was associated with lower central systolic and diastolic BP of - 1.17 mmHg (95% confidence interval (CI) - 2.07 to - 0.27 mmHg, P = 0.011) and - 0.74 mmHg (95% CI - 1.29 to - 0.18 mmHg, P = 0.009), respectively, as well as lower brachial systolic and diastolic BP of - 1.27 mmHg (95% CI - 2.20 to - 0.33 mmHg, P = 0.008) and - 1.00 (95% CI - 1.56 to - 0.44 mmHg, P = 0.001), respectively. PWV was not associated with GLP-1 release (P = 0.3). Individuals with the greatest quartile of GLP-1 response had clinically relevant lower BP measures compared to individuals with the lowest quartile of GLP-1 response (central systolic BP: - 4.94 (95% CI - 8.56 to - 1.31) mmHg, central diastolic BP: - 3.05 (95% CI - 5.29 to - 0.80) mmHg, brachial systolic BP: - 5.18 (95% CI - 8.94 to - 1.42) mmHg, and brachial diastolic BP: - 2.96 (95% CI - 5.26 to - 0.67) mmHg). Conclusion Greater glucose-stimulated GLP-1 responses were associated with clinically relevant lower central and peripheral blood pressures, consistent with beneficial effects on the cardiovascular system and reduced risk of CVD and mortality. Trial registration ClinicalTrials.gov Identifier: NCT00237549. Retrospectively registered 10 October 2005

KW - GLP-1

KW - Cardiovascular disease

KW - Central blood pressure

KW - Peripheral blood pressure

KW - Aortic stiffness

U2 - 10.1186/s12933-019-0937-7

DO - 10.1186/s12933-019-0937-7

M3 - Journal article

C2 - 31586493

VL - 18

JO - Cardiovascular Diabetology

JF - Cardiovascular Diabetology

SN - 1475-2840

IS - 1

M1 - 130

ER -

ID: 229062185